OR WAIT 15 SECS
The ovarian cancer arena across the seven major markets-US, France, Germany, Italy, Spain, the UK, and Japan-will increase from around $1.2 billion in 2015 to over $5.2 billion by 2025, a 15.5% rise, according to GlobalData.
The company released its latest report indicating the key driver of growth, the establishment of new standard of care (SOC) maintenance therapies in the first and second lines of treatment for newly diagnosed and recurrent patients. The anticipated extended durations of therapy in the maintenance settings should fuel the sales of poly ADP-ribose polymerase (PARP) inhibitors and immune checkpoint modulators, as their efficacy data is expected to justify their expensive price tags.
In the US, Lynparza is currently indicated for the fourth-line treatment of patients with a germline BRCA mutation. Rubraca received a label for the third line in the same patient population, but it also includes both germline and somatic BRCA. Although this was a success for Clovis, AstraZeneca is set to retake the lead after it announced top-line results from its Phase III SOLO2 study, which investigated Lynparza use in the second-line maintenance treatment setting.
To view GlobalData’s full report, click here.